• Medtide set plans to adopt a 2026 RSU Scheme, subject to shareholder approval at an extraordinary general meeting.
• Scheme mandate limit set at 10% of issued share capital on the adoption date, equal to 14,180,000 shares.
• Separate service provider sublimit proposed at 1% of issued share capital on the adoption date, equal to 1,418,000 shares.
• RSUs may be satisfied using existing H shares, newly issued H shares, or treasury shares transferred to a trust.
• Scheme term set at 10 years from the adoption date; awards generally carry a vesting period of at least 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtide Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260827-12301726), on August 27, 2026, and is solely responsible for the information contained therein.